SBIR/STTR Research Award

Discovery and development of single-subunit RNA polymerases for efficient RNA manufacturing

Award identifier ee47c1cc633bac1e7c3494b0b5ab45f37161a2e2dd74a71c5198bbb5b0145a06Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,963

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PRIMORDIAL GENETICS, INC.
Proposal award date
2018-09-17
Contract end date
2019-06-16
UEI
Y5AJZF5JMRD4
Solicitation number
PA18-574
Topic code
400

Research abstract

Project Summary AbstractRNA plays key roles in cells and organisms including as a carrier of protein coding information and as a regulator of gene expressionRNA therapeutics and RNA based vaccineswhich exploit the natural functions of RNA in creating physiological responses designed to prevent or treat diseasehave received increasing attention in the past few yearsparticularly for developing novel vaccines and for curing rare diseases caused by heritable genetic defectsThe expanded effort in RNA therapeutics and RNA vaccines has created a new demand for RNA molecules manufactured in large quantities to precise specificationsIn particularthe need to create RNA molecules andgtkb in length and to incorporate modified nucleotides for more efficient deliveryhigher stability and better clinical efficacyhas compounded this manufacturing problemAlthough RNAs have been produced enzymatically in vitro for several decades with the use of bacteriophage RNA polymerasesthe enzymes traditionally used to produce RNA for Randamp D purposes are not suited for the demanding specifications that apply to RNA molecules intended for RNA therapeuticsA new class of enzymeshighly optimized for synthesis of long RNAs with specific sequences and structuresneed to be created to meet this new demandIn this projectPrimordial Genetics aims to expresspurify and characterize known but so far untested single subunit RNA polymerases that can be used as starting reagents and genetic building blocks in the development of specialized RNA manufacturing enzymesWe will testdifferent enzymesrepresenting the natural diversity of bacteriophage RNA polymerasesfor their ability to meet the critical requirements for in vitro RNA synthesisincluding efficienthighyield RNA synthesisincorporation of non natural nucleotides and high RNA qualityThe two best enzymes will be improved by mutagenesis based on structural modelingusing the structural and functional information available for this class of enzymesThe proposed work is a feasibility study for isolating and developing novel enzymes suitable for RNA manufacturingand also for creating an enzyme development pipeline that can meet the varied needs for manufacturing a diversity of RNA sequencessizes and chemical structures represented in RNA vaccines and RNA therapeutic products under developmentThe enzymes discovered and improved in this work will be directly useful for RNA manufacturing applicationsand can be licensed or sold to companies developing RNA vaccines and therapeutics as well as companies building RNA manufacturing capabilities Project Narrative The principal aim of this project is to develop novel and improved RNA polymerasesenzymes used for manufacturing RNARNA vaccines and RNA medicines have steadily gained attention and investment as potentially revolutionary ways of protecting against disease and treating rare diseases caused by genetic defectsOne of the challenges with RNA based medicines is the production of clinical quantities of intacthigh quality RNA that is modified by incorporation of non natural building blocks that serve to stabilize the RNA and increase its efficacy in the human bodyDevelopment of novel RNA polymerases will help accelerate the development and production of this novel and highly promising class of therapeutics and vaccinesThis project can impact the prevention and treatment of viral diseases such as HIV and Hepatitis Band genetic diseases such as cystic fibrosis

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

8 SBIR/STTR records share this UEI (2013–2022). Reported award amounts total $5,066,438. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation, Department of Agriculture, Department of Energy

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.